Exicure (NASDAQ:XCUR) Enters into a Patent License Agreement with Bluejay Therapeutics

February 6, 2024

DENVER, Colo., Feb. 6, 2024 (247marketnews.com)- Exicure, Inc. (NASDAQ:XCUR) stated, this morning, that it entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis with Bluejay Therapeutics, a private clinical stage biopharmaceutical company focused on viral and liver diseases, in which Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment and Exicure will also be entitled to modest royalties on future net sales on all licensed technology by Bluejay during the term of the licensed patents.

Exicure is trading at $0.6701, up $0.1194 (+21.68%), on 2.9M shares traded.       

Its 52-week range is $0.3647 to $1.51.

“Our partnership with Bluejay continues the development of cavrotolimod,” said Paul Kang, Chief Executive Officer of Exicure. “Exicure has spent considerable resources to discover and develop cavrotolimod. While historically, we focused on oncology, Bluejay’s commitment and expertise in developing cavrotolimod for potential treatment of hepatitis makes them an ideal partner to expand the use case of cavrotolimod,” added Mr. Kang.

Exicure website: www.exicuretx.com.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.

Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.

Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (XCUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.